Research graph
References from Can we optimize the efficacy of aspirin for cardiovascular prevention?. Local targets link to admitted publications; unresolved targets remain external evidence.
A historical review of the biological, semantic and clinical aspects of aspirin resistance
10.1016/j.jtha.2026.06.027 · 2026 · External reference
Low-dose aspirin for the prevention of atherothrombosis
10.1056/nejmra052717 · 2005 · External reference
Laboratory detection of ‘aspirin resistance': what test should we use (if any)?
10.1093/eurheartj/ehm232 · 2007 · External reference
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease
10.1016/s0735-1097(02)03014-0 · 2003 · External reference
The platelet P2Y receptors as targets for new antithrombotic drugs
10.1046/j.1538-7836.2003.00286.x · 2003 · External reference
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity
10.1161/01.cir.0000072771.11429.83 · 2003 · External reference
Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance
10.1161/01.atv.0000145980.39477.a9 · 2004 · External reference
Pharmacological efficacy and gastrointestinal safety of different aspirin formulations for cardiovascular prevention: a narrative review
10.3390/jcdd10040137 · 2023 · External reference
Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus
10.1016/j.jacc.2016.11.050 · 2017 · External reference
Patients with essential thrombocythemia may be poor responders to enteric-coated aspirin, but not to plain aspirin
10.1055/s-0040-1714351 · 2020 · External reference
Effectiveness and safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease: a secondary analysis of the ADAPTABLE randomized clinical trial
10.1001/jamacardio.2023.3364 · 2023 · External reference
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
10.1016/s0140-6736(18)31133-4 · 2018 · External reference
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
1988 · External reference
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance.”
10.1016/j.jacc.2008.10.047 · 2009 · External reference
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes
10.1111/j.1538-7836.2012.04723.x · 2012 · External reference
Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease
10.1161/circinterventions.110.960187 · 2011 · External reference
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
10.1182/blood-2011-06-359224 · 2012 · External reference
Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?
10.3324/haematol.2022.281388 · 2023 · External reference
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: the ARES trial
10.1002/ajh.27418 · 2024 · External reference
